Autolus Therapeutics PLC
NASDAQ:AUTL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
UK |
|
Mare Engineering Group SpA
F:EZ3
|
IT |
|
O
|
Omni Bridgeway Ltd
OTC:IMMFF
|
AU |
Intrinsic Value
The intrinsic value of Autolus Therapeutics PLC (AUTL) under the Base Case is 2.398 USD per share.
Compared with the current market price of 1.545 USD, the stock appears
Undervalued by 36% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Autolus Therapeutics Does
Autolus Therapeutics is a biotech company that develops engineered T-cell therapies, better known as CAR-T treatments, for certain blood cancers. Its medicines are made from a patient’s own immune cells, which are collected, modified in a lab to attack cancer, and then given back to the patient. The company’s work sits in the highly specialized cell-therapy part of drug development, where the main goal is to turn living cells into targeted cancer treatments.
- Headquarters
- United Kingdom UK
- Employees
- 754
- IPO date
- Jun 22, 2018
Earnings Waterfall
Autolus Therapeutics PLC
The intrinsic value for Autolus Therapeutics PLC (AUTL) under the Base Case is 2.398 USD.
Compared with the current market price of 1.545 USD, the stock appears Undervalued by 36% .